Can adding common pain drugs reduce morphine needs in sickle cell crises?
NCT ID NCT07826988
First seen Sep 18, 2026 · Last updated Sep 18, 2026
Summary
Adults with sickle cell disease often face severe pain crises that require hospital treatment with intravenous morphine. This trial compares standard morphine treatment with combinations that add paracetamol, ketamine, or nefopam. Researchers want to see if these combinations ease pain faster and lower the total amount of morphine needed, which could reduce side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- paracetamol, ketamine, and nefopam added to morphine
- What this could lead to
- If successful, this could identify pain relief combinations that control sickle cell crises with lower morphine doses, reducing side effects like nausea and breathing problems.
- What could go wrong
- The trial may find that adding these medicines does not improve pain control or reduce morphine use. Each combination carries its own risks, such as sedation from ketamine or side effects from nefopam.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 400 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Jan 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult patients (age ≥18 years) * Diagnosed with major sickle cell syndrome (SS homozygous, SC or Sβ° or Sβ+ thalassemia compound heterozygous) * Hospitalized and presenting with a vaso-occlusive crisis (VOC), defined as acute pain or tenderness affecting at least one part of the body, including the limbs, ribs, sternum, head (skull), spine, and/or pelvis, not attributable to other causes * Requiring intravenous morphine or its derivatives * Informed consent obtained from the patient (or from a trusted support person, family member, or relative), or emergency inclusion procedure in cases where the patient is unable to consent and no trusted support person, family member, or relative is available Exclusion Criteria: * Refusal to participate * Pregnant or breastfeeding patient * Administration of one of the interventional group treatments within 4 hours prior to inclusion * Intravenous morphine treatment for more than 24 hours * Patient already included in the study within the previous 3 months * Patient receiving long-term opioid therapy * Not affiliated with a social security scheme, or patient under State Medical Aid (AME) * Patient under legal protection measures (guardianship / family authorization with representation mandate / future protection mandate) or under supervised guardianship (curatelle) * Patient deprived of liberty * Participation in another clinical trial involving a drug * Participation in the PAMAVOC trial within the previous 3 months * Contraindication to standard VOC treatment: * Hypersensitivity to opioids * Opioid-induced hyperalgesia, defined by increased pain on nociceptive testing, topographic extension, or the onset of allodynia with increasing opioid doses * Renal impairment, defined as creatinine clearance ≤30 mL/minute * Hepatocellular impairment, defined as prothrombin time \<40% * Impaired consciousness, defined as a Glasgow Coma Scale score ≤13/15 Exclusion from a Specific Intervention (randomization possible to other study arms): * Hypersensitivity to the active substance or to any of the excipients * Respective contraindications to nefopam, tramadol, ketoprofen, and ketamine, as described in their respective Summaries of Product Characteristics (SmPC)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Sickle cell disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gene editing offers hope for a One-Time sickle cell cure
- Tiny biochip could reveal sickle cell severity
- Can a milder transplant cure sickle cell and thalassemia in adults?
- Can an antioxidant supplement calm sickle cell blood cells?
- Can a softer transplant cure sickle cell disease?
- Mindfulness on your phone: a new test for sickle cell pain and sleep